Researchers develop a possible treatment for the most common types of cancer in children

Researchers at the University of “Cambridge” have developed a new double treatment that can open the door for hope for acute B-all-lymphocytes, the most common types of cancer in children. This treatment is expected to contribute to the improvement of healing opportunities, and reduce the dependence on chemotherapy known for its side effects, according to a new study published in the “Nature Communications” magazine. Although the study has been conducted on laboratory cells and experimental mice so far, the research team will soon be financing with clinical experiences on people. Acute lymphaticemia affects acute B-all lymphatic leukemia over 500 people annually in the UK, 40% of them are children. Despite the possibility of recovery in most cases in young people, the treatment needs more than two years of intense chemotherapy, leaving patients vulnerable to infection, and exposes it to serious side effects, such as hair loss, nausea, vomiting, bruising and bleeding, in addition to long -term complications that can affect nerves, joints and hearts. When it comes to adolescents and adults, the results are often worse. The researchers have developed a mixture of two medicines, “venetoclax” and “inobrodib”. The first is currently used to treat a different type of leukemia, but it is not permanently effective against acute lymphatic leukemia. Here comes the role of “inoprrodip”, a new drug developed by Celentric University of Cambridge. The medicine disrupts the CRIBBP gene, which leads to a change in the method of cells that consume fats, which make it vulnerable to a unique kind of “programmed cell death”, known as “ferroptosis”, and it differs from the death of classic cells, and occurs due to damage to cell membranes through oxidized fat. Crebbp -no is responsible for producing a protein that plays an important role in organizing the activity of many genes in cells, by adapting the DNA structure and facilitating the process of copying genes. This protein works as an important organizer in the growth and distribution of cells, and also contributes to the control of infections and immune response. In cases, such as acute B-all lymphs, mutations can perform, or the function of this gene disrupts to a defect in regulating the growth of cancer cells, and increasing their resistance to chemotherapy, making it a central goal in research to develop more effective treatments. The death of the programmed cells is considered a kind of programmed cell death, which is different from other forms such as ‘Samatic’, and is characterized by the accumulation of iron and oxidative damage that affects fat in the cell membranes, which eventually leads to the disintegration and death of the cell. This type of cell death occurs when the cell fails to protect itself from oxidation reactions that target fat, and iron is an essential element to accelerate this process. It is also important in a number of diseases such as cancer and neurological diseases, and it has become an emerging purpose in developing new treatments, especially for cancer that shows resistance to traditional treatments, such as some types of leukemia. When integrating “inoprrodip” with “venetoclas”, the effective elimination of the B cells was noticed, even those resistant to treatment. While cancerous B -cells have undergone a type of white blood cells, which is responsible for the production of antibodies, to cancerous transformation, which led to their reproductive production and the formation of crops in the lymphatic system. Genetic mutations and these cells arise as a result of genetic mutations that cause a defect in the mechanism of programmed cell death and cell division, and their most common types include chronic lymphatic leukemia, non -vuchantomy and multiple rays. These cells differ from the natural cells in their shape, size and behavior, because they lose their ability to perform their immune function properly while continuing to reproduce, which impedes the work of the immune system, and causes symptoms such as enlarged lymph nodes, anemia and increases the risk of infection. Its treatment also depends on the type and stage of the crop, and in some cases contains chemotherapy, immune therapy and stem cell transplantation. Although the study is still in its early stages, and only on mice, the results are very encouraging. “An important feature” and the greatest benefit of this approach lies in the fact that it does not eliminate the B cells permanently as some modern treatments do, such as car-t immunological therapy, which allows the body to reproduce it after it has stopped the treatment, thus reducing the risk of the immune system in the long run. The story of Gil Murphy, who was diagnosed with that kind of cancer in 2013, sheds light on the acute suffering that patients go through. After thinking that her symptoms were caused by simple anemia, she was found to have leukemia, and that she spent long weeks in hospital to receive chemotherapy, and his hard effects of hair loss, nausea and deprivation of her child’s vision due to poor immunity. “I was dealing with the disease as a project to be done, but over time the fear grew greater, and there was long nights without sleep,” Generation said. After undergoing stem cell transplantation, she managed to achieve recovery, but today she lives what she describes as a ‘new normal situation’ with permanent side effects such as exhaustion, diabetes and cognitive problems. However, a generation has found a new meaning for her life as she has become an ambassador for the ‘Bachelor’s Cancer’ in the UK, and she has moved her experience and contributes to the support of other patients, and emphasizes that the treatment situation is much better than it was 12 years ago today. Clinical experiments The Cambridge University team seeks to launch clinical experiences soon, and utilize the expected cost of the medicine “Veitoclux”, with “a genealogy of the drug” in the market (medicine that corresponds to the innovative agent), which can make this treatment more available. Cambridge Research Hospital in Cambridge is also underway with the “Adenbrok” ​​Hospital Fund, which aims to accelerate the frequency of medical discoveries and generalize its benefits for cancer patients in the UK.